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Abstract
In human and animal transmissible spongiform encephalopathies (TSEs) or prion disorders, 
biochemical analysis of disease-associated prion protein (PrPTSE) is a first-line approach for 
large scale routine testing and for a rapid molecular typing. This characterization is based 
on conformational properties of PrPTSE enciphered in its secondary and tertiary structures 
and on glycosylation profile. Several biochemical approaches are helpful in distinguishing 
PrPTSE forms in human prion diseases. In particular, in sporadic Creutzfedlt-Jakob disease 
(CJD), PrPTSE is characterized by two main glycotypes conventionally named PrPTSE type 
1 and PrPTSE type 2 based on the apparent gel migration at 19 kDa and 17.5 kDa and gly-
cofrom ratio. Further, there are PrPTSE low molecular weight fragments which correlate to 
distinct phenotypes of sCJD. Finally, by using two-dimensional PAGE analysis, which sepa-
rates PrPTSE on both isoelectric point and molecular size, we were able to detect two distinct 
migration pattern in PrPTSE type 2, one in subjects with MM at codon 129 and another in 
MV, VV. We here provide an extensive PrPTSE biochemical analysis in humans and animals 
affected with prion disorders. Further, we showed that PrPTSE glycotypes observed in CJD 
shared similarities with PrPTSE in bovine spongiform encephalopathies (BSEs). These signa-
ture similarities obtained by a biochemical analysis had been further confirmed by experi-
mental transmission.
Keywords: prion protein, pathological prion protein, transmissible spongiform 
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1. Introduction
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal neurodegenera-
tive disorders affecting humans and animals with a sporadic, genetic, or iatrogenic etiology [1]. 
The crucial event in the pathogenesis of TSEs is the conformational conversion of the normal 
cellular prion protein (PrPC) into a pathologic isoform (PrPTSE), which is self-propagating and 
infectious [2]. PrPC is a glycosylphosphatidylinositol (GPI) anchored protein residing on the 
outer leaflet of the cellular membrane of most cell types in mammals. It is synthetized as 253 
amino acids polypeptide before being posttranscriptionally modified by the cleavages of 22 
amino acids of signal sequence at N-terminal and of 23 amino acids at the C-terminal for adding 
GPI anchor. The mature protein contains a disulfide bond between Cys179 and Cys214 and can 
be glycosylated at Asn181 and Asn197. While PrP N-terminus contains a variable number of 
octapeptide repeats, it is flexible and disordered, and C-terminus is more structured in a globu-
lar domain characterized by three α-helixes and two short β-sheet structures [3]. Structurally, 
PrPC contains mainly α-helix structures, while PrPTSE contains β-sheet structures [4]. These 
conformational changes in secondary and tertiary structures determine PrPTSE specific physi-
cochemical changes such as PK resistance, insolubility in nonionic detergents and high propen-
sity to aggregate in oligomers of different size [5]. It has been assessed that PrPTSE conformations 
are related to distinct prion strains, which propagate with specific transmission properties in 
susceptible mammals (different infectious properties, incubation times or neuropathological 
lesions) [6]. Aim of the present chapter is to describe different biochemical strategies to charac-
terize molecular features and biochemical properties of prions in humans and animals.
1.1. Defining molecular features of prions by biochemical analysis, cellular and disease-
associated PrP biochemical characterization
A suitable way to detect and reveal PrPC and PrPTSE is Western Blot analysis following electropho-
retic mono-dimensional (1D) separation [7]. Electrophoretic analysis provides information about 
glycotype based on PrP molecular weight and glycosylation profile [8]. Two-dimensional (2D) 
electrophoretic analysis is a more in depth analysis to investigate the molecular features of pro-
teins, improving the resolution since a single amino acid substitution in PrP sequence, glycosyl-
ation profile or the presence or absence of GPI anchor is sufficient for determining a shift pointing 
migration. The goal of 2D electrophoresis is to characterize PrPTSE molecular signature typical of 
each prion strain, more accurate and specific than simple classical 1D electrophoretic pattern.
1.2. Conformational assays to characterize PrPTSE biochemical properties in human and 
animal prion disorders
Several simple biochemical methods can be used to investigate conformational features of 
different biochemical prion strains.
1.2.1. Resistance to proteinase K treatment
Western blot analysis following PK digestion allows the detection of PK-resistant PrP, also 
termed PrP27-30. This method is routinely used to confirm TSEs diagnosis.
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Biochemical strains of PrPTSE can be defined also by the presence of PK resistant additional 
minor C-terminally truncated fragments (CTFs).
1.2.2. Detergent insolubility and separation by size of PrPTSE aggregates
The high representation of β-sheet structures is a requisite of PrPTSE to form insoluble aggre-
gates in nonionic detergents. By ultracentrifugation, enriched fractions of PrPTSE can be pre-
pared and separated by different size of aggregates in sucrose gradients. This analysis allows 
to characterize PrPTSE conformational properties in a given prion strains.
1.2.3. Conformational stability in increasing concentration of GdnHCl
Different prion strains show different conformational stability, which can be assessed by 
PK-resistance testing following exposure to different denaturing or nondenaturing conditions.
2. PrP conformers and disease phenotypes in human and animal TSEs
2.1. 1D analysis of molecular strains
2.1.1. Human prion disorders
2.1.1.1. Sporadic forms
In human prion disorders, several different PrPTSE types have been described, based on the 
electrophoretic migration and the glycosylation profile of PrP27-30. This is composed of a major 
triplet of bands, which represent the differently glycosylated isoforms of PrPTSE. Since prions are 
associated with distinct conformations, biochemical analyzes are useful to define prion strains.
In human sporadic CJD, PrPTSE separates as two main glycotypes: PrPTSE type 1 and PrPTSE 
type 2A with an apparent gel migration of the unglycosylated isoform at 21 kDa and 19 kDa 
respectively (Figure 1A) [9]. Type-1 and 2A show similar glycosylation profile (Figure 1B).
In 2007, we reported on a novel PrPTSE glycotype, showing a predominant unglycosylated 
isoform and slightly the monoglicosylated isoform, but completely lacking the diglycosylated 
one, named Type-U (Figure 1A and B) [10].
In 2010, an additional form of prion disease has been described, called variably protease-
sensitive prionopathy (VPSPr). VPSPr is characterized not only by a distinct disease phe-
notype but also by a ladder-like electrophoretic profile of the PK-resistant PrPTSE fragments 
(Figure 1C). The ladder-like profile consisted of five major bands migrating at approximately 
26 kDa, 23 kDa, 20 kDa, 17 kDa, and 7 kDa [11].
2.1.1.2. Genetic forms
Familial prion diseases, FFI and GSS are characterized by distinct biochemical profiles, with typi-
cal migration properties, glycosylation profiles or truncated fragments expression. While fCJD 
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and FFI show the presence of PrP27-30 differentially PK cleaved and glycosylated, in GSS PrP27-
30 is absent, pathological PrP is composed of internal fragments of 8 and 11 kDa with the exception 
of P102L. P102L shows a peculiar pattern with the presence of both PrP27-30 and 8 kDa internal 
fragment. Familial prion diseases western blot is schematically reported in Figure 1C [12–14].
2.1.1.3. Infectious form
Following BSE transmission to humans causing variant CJD (vCJD), a new human molecular 
strain was defined (type 2B) with a molecular weight comparable to type 2A but with a preva-
lent diglycosylated isoform (Figure 1C) [15].
2.1.2. Size aggregates
Since the abundance of β-sheet in the secondary structure of PrPTSE confers the tendency 
to aggregate, ultracentrifugation procedures can be applied to discriminate different con-
Figure 1. (A) Western blot profile of three sCJD molecular strains and their relative glycoform profile (B). (C) Schematic 
representation of human western blot profile of sporadic, genetic and acquired CJD molecular types.
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formational states associated with different prion strains. By using ultracentrifugation in 
sucrose gradients and sarkosyl, insolubility and the size of PrPTSE aggregates can be com-
pared [16].
The three sporadic molecular subtypes are characterized by distinct sedimentation patterns, 
considering ultracentrifugation analysis before and after PK treatment (Figure 2). MV-1 PrP 
species are distributed at the beginning and at the end of the gradient, indicating the pres-
ence of small soluble forms and big insoluble aggregates; this distribution is maintained 
also after PK treatment. MV-2 sedimentation pattern of cellular PrP is characterized by a 
wide distribution all over the gradient, while after PK digestion PrPTSE is detected as big 
insoluble aggregates at the end of the gradient. MV-U sedimentation pattern of cellular PrP 
is comparable to MV-1, but PrPTSE species are found mainly at the bottom of the gradient as 
for MV-2.
2.1.3. Conformational stability assay
Sporadic human strains can be distinguished also by testing the strength of three dimensional 
protein structure against denaturing conditions. This is investigated by PK treatment after 
exposure to increasing amounts of guanidine [17].
In Figure 3, it can be noted that in MV-1 and MV-2, the structure integrity is maintained 
until an exposition to 2 M guanidine before PK can completely digest the protein; in MV-U, a 
concentration of 1.5 M is enough to unfold the PrPTSE. It's interesting to note that in MV-U at 
a 1.0 M guanidine concentration, PK digestion produces two conformers of PrPTSE at different 
molecular weights, indicating that two molecular strains are hidden in the three dimensional 
conformation (unpublished data). Inoculation experiments in bank voles have shown this 
MV-U case contains two different strains with different incubation time and different lesion 
profile associated with two different molecular electrophoretic patterns after transmission 
(unpublished data).
Figure 2. Fractionation of sCJD PrP aggregates. Brain homogenates from frontal cortexes of MV-1 and MV-2 and MV-U 
were sedimented in a 10–60% sucrose gradient. After sedimentation, half samples were digested with PK. Relative 
cellular (black) and PK resistant (gray) percentage of fraction distribution in MV-1 (A), MV-2 (B) and MV-U (C).
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2.2. 2D analysis of molecular strains
2.2.1. Molecular signature
2D analysis of PK and PNGase treated samples gives trains of spots corresponding to the nude 
N-ragged ended isoforms of the prion core fragment. Western blot using antibodies against 
the C-terminal of prions evidences also the presence of truncated fragments (CTFs) [18].
Two-dimensional immunoblot with anti-PrP antibodies gives the possibility to identify two 
groups of C-terminal protease-resistant PrP fragments. All sCJD cases with type 1 PrP27-30, in 
addition to MM subjects with type 2 PrP27-30, are characterized by the presence of CTFs of 
16–17 kDa and 12–14 kDa. Conversely, brain homogenates from VV and MV patients with type 2 
PrP27-30 contain CTFs migrating at 17.5–18 kDa. Therefore, we can conclude that the mechanism 
involved in the formation of CTFs is not influenced by codon 129 and by the type of PrP27-30.
Based on the biochemical patterns obtained by combining the PrP27-30 core fragment and 
lower truncated PrP species, three distinct groups or fingerprints of disease-associated PrP spe-
cies in sCJD with type 1 PrPTSE, MM2 subjects, and MV2/VV2 cases can be defined (Figure 4).
2.2.2. GPI anchor
PrP posttransductional modifications, such as the presence of GPI anchor can be easily inves-
tigated by 2D analysis [1]. 2D molecular coordinates (pI and Mw) of GPI anchor were cal-
culated by comparing the unglycosylated PrP in wild type and anchorless transgenic mice. 
By 2D analysis, we can compare the 2D coordinates of known recombinant peptides with 
Figure 3. Relative quantification of denaturation transitions for MV-1, MV-2 and MV-U types.
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unknown samples to see if their 2D coordinates correspond to the nude peptides of are shifted 
by the “weight” of the GPI anchor. Since recombinant protein molecular coordinates in 2D 
analysis correspond exactly to the theoretical values (Figure 5), anchored or anchorless prions 
can be identified by only valuating if the measured pI and Mw correspond to the theoretical 
ones with or without GPI weight.
Figure 4. Two-dimensional mapping of sCJD brain homogenates after PK treatment (A–C) and deglycosylation (D–F) 
with anti-C–terminal antibody. Schematic diagram of PK-resistant C-terminal PrP core fragments in sCJD subtypes. (G, 
H, I) [17].
Figure 5. Two-dimensional mapping of synthetic PrP peptides [1].
Molecular Signature in Human and Animal Prion Disorders
http://dx.doi.org/10.5772/67329
97
Figure 6 represents a schematic picture of PrPTSE core fragment after 2D analysis [1].
All the sCJD molecular type 1 and 2 subtypes have all the 27–30 isoforms with a pI more 
acidic than pH 7 except the group MV-2/VV-2 showing an extra isoform at pI ~ 8. This last 
isoform has the same molecular coordinates of the synthetic peptide 90–231 and corresponds 
to anchorless form. All other spots identify anchored PrPTSE forms, since their pI is shifted 
about 1 pH unit toward the acidic pole.
2.3. Cattle
2.3.1. Animal prion disorders
Since it was known, BSE was always described by the same molecular strain characterized by a 
diglycosylated electrophoretic pattern. In 2004, in Italy, two old cows were described by Zanusso 
et al. as showing a lower molecular weight of the prion core fragment and a different glycosylation 
pattern at western blot [19]. In 2007, other cases were found in France with classical glycosylation 
profile but with higher molecular weight of the prion electrophoretic profile (Figure 7) [20]. These 
new atypical molecular types where named BASE (bovine amyloidotic spongiform encephalopa-
thy) or L-type BSE and H-type BSE considering the lower or higher western blot profile. The three 
molecular profiles also reflect different clinicopathological features of the diseases [21].
Figure 6. Schematic representation of anchored and anchorless PK-resistant PrP core fragments in sCJD subtypes.
Figure 7. (A) Western blot profile of three BSE molecular strains and their relative glycoform profile (B).
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2.3.1.1. Size aggregates
Ultracentrifugation analysis before PK treatment shows a similar sedimentation pattern in the 
three cattle molecular subtypes: samples present both small soluble forms and large insoluble 
aggregates. The treatment with PK shows PrPTSE is present in the insoluble aggregates in all 
BSE strains (Figure 8); moreover, aclassical BSE shows also an additional small amount of 
soluble forms (Figure 8C).
2.3.1.2. Conformational stability assay
Both atypical forms of BSE can be distinguished from classical BSE and also human sCJD on the 
basis of structure denaturation by chaotropic agents such as guanidine. While human sporadic 
PrPTSE is digested after an exposition over 2 M guanidine, all BSE forms maintain a minimal 
Pk resistance until 3 M guanidine. Among BSEs, C-type is shown to be strongly resistant to Pk 
digestion until 2 M guanidine, while H- and L-type resistances are stable until 2.5 M (Figure 9).
Figure 8. Fractionation of BSE PrP aggregates. Brain homogenates from frontal cortexes of H-BSE and L-BS and C-BSE 
were sedimented in a 10–60% sucrose gradient. After sedimentation, half samples were digested with PK. Relative 
cellular (gray) and PK resistant (black) percentage of fraction distribution in H-BSE (A), L-BSE (B) and C-BSE (C).
Figure 9. Relative quantification of denaturation transitions for the H-BSE, C-BSE, and L-BSE.
Molecular Signature in Human and Animal Prion Disorders
http://dx.doi.org/10.5772/67329
99
2.3.1.3. Molecular signature
In Figure 10, 2D analysis of typical and atypical BSE shows that the three forms of BSE correlate 
to three distinct signatures. H-type BSE shows a consistent representation of truncated fragments 
at 12 kDa, while C-type and L-type molecular fingerprint is mainly characterized by 27–30 PrP.
2.3.1.4. GPI anchor
In the three forms of BSE, PrP27-30 core fragment is characterized by two sets of isoforms dif-
fering of ~ 1.0 unit of pI and ~2.0 kDa (Figure 11).
The comparison between theoretical and measured isoelectric points and molecular weights 
of core fragments indicates that the upper set represents anchored forms.
Therefore, classical BSE shows only one anchorless isoform, while in L-BSE and H-BSE, there 
are three anchorless isoforms with average amount comparable to the anchored ones.
2.4. Molecular similarities between human and cattle TSE forms
2.4.1. Comparison of human and cattle molecular strains by 1D analysis
In Figure 12, biochemical PrPTSE types are matched two by two to best compare the molecular 
similarities. sCJD type 1 and H-type BSE share the same molecular weight; sCJD type 2A and 
L-type BSE show similar molecular weight and glycosylation profile; vCJD and classical BSE 
are characterized by a similar diglycosylated profile.
Figure 10. Two-dimensional mapping of BSE brain homogenates after PK treatment. Schematic diagram of PK-resistant 
C-terminal PrP core fragments in BSE strains (A–C).
Figure 11. Schematic representation of anchored and anchorless PK-resistant PrP core fragments in BSE strains.
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2.4.2. Comparison of human and cattle molecular strains by 2D analysis
Increasing resolution power by 2D analysis, it's possible to deeply compare biochemical sig-
natures of PrPTSE between humans and cattle (Figure 13). PrPTSE shows similar signatures in 
BSE-H and sCJD type 1 and is characterized by the dominance of C-terminal fragments. These 
patterns are distinct from those observed in other forms. Both sCJD type 2A and L-type BSE 
show the same set of spot at about 18 kDa, while in vCJD and L-BSE the molecular signature 
seems to be different.
2.4.3. Comparison of human and cattle molecular strains by 2D analysis after experimental 
transmission
A lot of experimental transmission studies have been performed to define prion strains from small 
animals such as mice or hamster to highly evolved primates such as chimpanzees or macaques. 
Transmission studies in transgenic mice, carrying one or more human or bovine prion gene copy, 
are often a useful approach to investigate the relationship among different prion strains [22].
Nevertheless primates can be considered the host nearest to humans. In fact, several interest-
ing similarities between human and cattle strains can be enhanced by molecular analysis after 
transmission experiments to primates.
sCJD MM-1 and sCJD MM-1 after experimental transmission to primate share identical pat-
terns of PrP27-30 and C-terminal fragments (CTFs) indicating that PrPSc fingerprints are con-
served throughout transmission as reported in Figure 14. This finding confirms that primates 
are a good model to simulate transmission to humans of human prion strains.
In Figure 15, it can be noted that C-BSE shows the appearance of CTFs after first passage 
transmission, which maintains an identical pattern at second passage.
vCJD and vCJD passaged to primate share the same PrPTSE fingerprints identical to those 
observed in BSE at first and second passage (Figure 16). This is a further confirmation of the 
correlation between BSE and vCJD.
Figure 12. Western blot profile (A) and schematic representation of paired human and BSE strains (B).
Molecular Signature in Human and Animal Prion Disorders
http://dx.doi.org/10.5772/67329
101
Figure 13. 2D western blot comparison between human and cattle TSE.
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Figure 17 shows L-BSE PrPTSE CTFs pattern in primate similar to that of L-BSE in cattle, char-
acterized by a set of fragments migrating at 18 kDa; this set of spots are absent in BSE and 
vCJD passaged to primates. It's to be noted that L-BSE transmitted to primate is almost identi-
cal to human MV-2. These molecular signature similarities confirm molecular pattern previ-
ously observed for 1D immunoblot and suggests a possible molecular common origin of the 
two molecular strains. This correlation however needs to be deeply analyzed and confirmed.
Figure 14. 2D western blot comparison between human MM-1 before and after transmission to primate.
Figure 15. 2D western blot comparison between C-BSE before and after transmission at first and second passage to 
primate.
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3. Conclusions
We have shown that molecular analysis of prions is a powerful approach to characterize 
prions.
Figure 16. 2D western blot comparison between vCJD before and after transmission to primate and C-BSE after second 
passage to primate.
Figure 17. 2D western blot comparison between L-BSE before and after transmission to primate.
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By using several different biochemical approaches, it's possible to enhance molecular differ-
ences and similarities to define prion strains.
In particular, biochemical analysis is shown to be rapid and informative in:
 – differentiation of PrPTSE strains;
 – correlation of molecular to clinicopoathological phenotypes;
 – large scale epidemiological studies and surveillance: finding and discriminating strains 
(sCJD, vCJD, atypical BSEs).
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